Mitochondria as a drug target in ischemic heart disease and cardiomyopathy.
Ischemic heart disease is a significant cause of morbidity and mortality in Western society. Although interventions, such as thrombolysis and percutaneous coronary intervention, have proven efficacious in ischemia and reperfusion injury, the underlying pathological process of ischemic heart disease, laboratory studies suggest further protection is possible, and an expansive research effort is aimed at bringing new therapeutic options to the clinic. Mitochondrial dysfunction plays a key role in the pathogenesis of ischemia and reperfusion injury and cardiomyopathy. However, despite promising mitochondria-targeted drugs emerging from the laboratory, very few have successfully completed clinical trials. As such, the mitochondrion is a potential untapped target for new ischemic heart disease and cardiomyopathy therapies. Notably, there are a number of overlapping therapies for both these diseases, and as such novel therapeutic options for one condition may find use in the other. This review summarizes efforts to date in targeting mitochondria for ischemic heart disease and cardiomyopathy therapy and outlines emerging drug targets in this field.
School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY 14642, USA.
Andrew M
AM
Walters
George A
GA
Porter
Paul S
PS
Brookes
D000818:Animals; D009202:Cardiomyopathies / Q000188:drug therapy / Q000503:physiopathology*; D002317:Cardiovascular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D006801:Humans; D008929:Mitochondria, Heart / Q000187:drug effects* / Q000502:physiology; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000503:physiopathology*; D016896:Treatment Outcome
D002317:Cardiovascular Agents